TCGX

Today marks the culmination of seven months of hard work to eclipse our $1.2B target and reach the $1.3B hard cap of capital commitment from both existing and new limited partners as part of our recently oversubscribed TCGX Fund III.    TCGX continues to support companies developing novel therapies in disease indications where there are critical unmet needs with breakthrough medicines & innovative therapeutics. The investment team at TCGX led by Founding Partner, Chen Yu, and led by co-Managing Partners, Cariad Chester & Giuliano Marostica, are driving the efforts to partner with biotech CEOs who are at the forefront of biotechnology & life science innovation.   After the launch of its inaugural fund, TCGX Fund I, at the peak of biotech valuations in February of 2021, the team has successfully raised >$3B of capital commitments from limited partners globally supported by the excellent performance of the investment team working alongside Chen, Cariad, & Giuliano, notably Dandan Dong, George Feng, Haithem Laaribi, Suan Tuang, M.D., Ph.D., Michael Albert, and Bill Zhang, as well as our Head of Trading, Brad Balter, and the operations & finance team, led by our CFO & COO, Craig Skaling, Jing Wu, Echo Qin, Kate Garcia, & Bow Papanos. As the Head of Capital Formation & Investor Relations, Ed Amorosi, I would like to extend deep gratitude to our incredible team and to our limited partners for making this milestone possible. We look forward to supporting the next wave of breakthrough medicines for patients and thank you to all of our limited partners for their continued collaboration. We are thrilled to be working with you in this exciting moment in biotech.   Full press release here: https://lnkd.in/gNwR23md

Sanofi to acquire next-generation vaccine biotech Vicebio for $1.6 billion. The acquisition follows the successful close of a $100 million Series B round led by TCGX and exciting clinical data from our lead program, an RSV/hMPV bivalent vaccine. Cariad Chester, Managing Partner TCGX, had this to say about the fantastic news: "Vicebio has successfully developed best-in-class multivalent vaccines targeting leading causes of respiratory disease. These vaccines have the potential to protect millions of patients from life-threatening viral infections and we are thrilled to partner with Sanofi to accelerate their development. We look forward to working with Sanofi and combining our innovative technology with Sanofi's global clinical development capability." We want to thank Emmanuel Hanon for his expert leadership and all the Board Members for their hard work to achieve this exciting outcome: Moncef Slaoui, Khurem Farooq, Giovanni Mariggi, Aaron Royston, M.D., Mark Chin, and Dr Craig Belcher MBA GAICD RTTP. Please read the full press release here: https://lnkd.in/eEhr_9qF https://lnkd.in/ed9wx3zp

We are pleased to announce that TCGX led the $135 million Series B financing of Adcendo, a first-in-class Danish biotech company developing ADC programs for the treatment of cancers with high unmet needs. Cariad Chester, Managing Partner of TCGX, joined Adcendo’s Board of Directors and commented: "ADCs have transformed the clinical landscape and standard of care in the treatment of solid tumors. Continued progress for hard-to-treat cancers will require innovative approaches and I’m confident Adcendo will be a leader in the next era of ADC drug development. With this financing, Adcendo can rapidly advance a pipeline of exciting, differentiated ADC candidates. These programs have the potential to significantly change the treatment paradigm in multiple cancers and serve patients in need of better therapies.” Please read more about this development via: https://lnkd.in/e6VCBxDm.